



CEO Board Report

Seth Berkley, MD
Chief Executive Officer

GAVI Alliance Board meeting
Geneva, Switzerland

11-12 June 2013

Overview of presentation

- Results
- Accelerated vaccine support
- Hot topics
- Expenditure and resources – horizon view
- Opportunities and challenges
- Board agenda: key decisions and discussions

Progress Report 2012 launched today

Print and multimedia package



Impact in the Meningitis Belt

103 million
people immunised

Impact:


Number of MenA cases:

| | 2008 | 2012 |
|--------------|------|------|
| Niger | 842 | 0 |
| Burkina Faso | 156 | 0 |
| Mali | 16 | 0 |

Price of vaccine package falls

Change in the total cost to fully immunise a child with pentavalent, pneumococcal and rotavirus vaccines
Selected vaccine package price (US\$)

- *April 2013:*
new lowest price for pentavalent vaccine:
US\$ 1.19 per dose



* Future targets are not publicised to avoid setting a minimum price.

HPV vaccine price drops - May 2013

THE AUSTRALIAN
REPORTING THE FACTS

Cervical cancer vaccine

From AAP
 TWO million
 Starting more than
 The plan that's w
 childho

"This i
 Dr Set
 Immu
 "A vi
 we c
 matt
 Dru
 the

Citrus
 Is R
 AVON PR
 the over
 try to a
 sure she
 Althoug
 growth
 funds in
 she, "W
 "I'm

In Its Efforts to Integrate Roma, Slovakia Recalls U.S. Struggles
BY ANDREW WIGGINS
 SLOVAKIA'S ROMANY
 Roma - living in a
 ghettos - are being
 to work, the govern
 the Roma people of
 Slovakia.



...companies dramatically
 HPV vaccine costs for girls in
 developing world
 (Jessica Rinaldi/Reuters)

Price slashed
 for cancer
 vaccine in
 poor nations

The New York Times
 VOL. CLXII, No. 56,132
 NEW YORK, FRIDAY, MAY 10, 2013

Zimbabwe Star
 From Zambezi to Limpopo

After Plant Explosion, Texas Remains Wary of Regulation

English.news.cn
新华网 NEWS

FINANCIAL TIMES
 May 9, 2013 6:21 pm
GSK and Merck vaccine deal
 By Andrew Jack

ShanghaiDaily.com
GAVI gets HPV vaccine deals at record low price for developing countries
 Source: XINHUA | 2013-5-10 | ONLINE EDITION
 GENEVA, May 9 (Xinhua) -- A record low price for HPV vaccine announced Thursday.
 ensure millions of girls in developing countries will have access to the vaccine.
 The poorest countries will now have access to the vaccine at a price as low as 4.50 U.S. dollars per dose. The same price was previously paid for the vaccine in developed countries and the previous price was 12.50 U.S. dollars per dose.

GAVI gets HPV vaccine price for developing countries
 English.news.cn 2013-05-10 08:09:08
 GENEVA, May 9 (Xinhua) -- A record low price for HPV vaccine announced Thursday.
 ensure millions of girls in developing countries will have access to the vaccine.
 The poorest countries will now have access to the vaccine at a price as low as 4.50 U.S. dollars per dose. The same price was previously paid for the vaccine in developed countries and the previous price was 12.50 U.S. dollars per dose.




SPIEGEL ONLINE GESUNDHEIT

Gebärmutterhalskrebs: Initiative drückt Preis für HPV-Impfung in armen Ländern auf Rekordtief
 Die Impfung soll Millionen Mädchen vor Gebärmutterhalskrebs schützen: Einer Initiative ist es gelungen, den Preis für HPV-Impfstoffe in den ärmsten Ländern der Welt auf ein Rekordtief zu senken. Noch in diesem Monat starten erste Impfkampagnen.

A cervical cancer vaccine of the world's poorest countries
 Merck and GlaxoSmithKline have discounted bulk quantities of the vaccine for the poorest countries.
 The action follows the GAVI Alliance's decision to purchase the vaccine at a record low price.

GAVI Alliance Board meeting
 11-12 June 2013





**Kenya
HPV vaccine**

| | | | |
|-----------------------|--|--------------|--|
| Serial No. | | 002 | |
| Name | | RAHMA SAID | |
| Date of Birth | | | |
| Household Head Name | | NASHA SAID | |
| Name of school | | PRIMARY S.K. | |
| Next Vaccination Date | | July 2013 | |

| | | | |
|-----------------------|--|-------------------|--|
| Serial No. | | 001 | |
| Name | | DUNYA M. M. M. M. | |
| Date of Birth | | | |
| Household Head Name | | DUNYA M. M. M. M. | |
| Name of school | | PRIMARY S.K. | |
| Next Vaccination Date | | July 2013 | |

| | | | |
|-----------------------|--|--------------|--|
| Serial No. | | 003 | |
| Name | | NASHA SAID | |
| Date of Birth | | | |
| Household Head Name | | NASHA SAID | |
| Name of school | | PRIMARY S.K. | |
| Next Vaccination Date | | July 2013 | |




Rwanda
Measles-rubella vaccine



Somalia
Pentavalent vaccine

Impact on the ground

Eliminating Hib meningitis in Kenya (Kilifi district)



Source: Anthony Scott, Wellcome Trust Senior Research Fellow in Clinical Science
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Donors rank GAVI in top two: MOPAN multilateral aid review - December 2012

- Multilateral Organisation Performance Assessment Network (MOPAN) includes 13 donors representing over 70% of GAVI's resources
- Country-level surveys in 15 GAVI-eligible countries
- “GAVI is strongly promoting a corporate focus on the achievement of results”
- “Relationships management is one of GAVI's strengths”
- “GAVI support of country ownership and its alignment and harmonisation...highly appreciated by survey respondents”
- Room for improvement includes indicators for Paris Declaration commitments

High level panel prioritises immunisation in post-2015 agenda



Immunisation and Education outcomes



Public Private Partnerships

21st Century Development Models

A NEW GLOBAL PARTNERSHIP: ERADICATE POVERTY AND TRANSFORM ECONOMIES THROUGH SUSTAINABLE DEVELOPMENT

The Report of the High-Level Panel of Eminent Persons on the Post-2015 Development Agenda




4. Ensure Healthy Lives

4b. Increase by x% the proportion of children, of children, adolescents, at-risk adults and older people that are fully vaccinated




Accelerated vaccine support

Accelerating vaccine support to developing countries




Vaccine introductions 2013



Hot topics – a quick scan around the world


Reported Measles Incidence Rate: April 2012 – March 2013

15 large outbreaks since Jan 2012



Largest study of childhood diarrhoeal diseases confirms rotavirus as leading cause

Global Enteric Multicenter Study (GEMS)




- Study of over 22,000 children in sub-Saharan Africa and South Asia
- Nearly 8.5-fold increased risk of death in infancy for moderate to severe diarrhoea

“...rotavirus is the most common cause of moderate-to-severe diarrhoea at every site during the first year of life...”

“Therefore, rotavirus vaccination should be deployed in all countries”


The Lancet, 14 May 2013

Integrated Global Action Plan for Pneumonia and Diarrhoea - WHO & UNICEF, April 2013




Source: The integrated Global Action Plan for Pneumonia and Diarrhoea, Unicef/WHO 2013 (adapted from PATH)

Polio Eradication and Endgame Strategic Plan (2013-2018)



2024 – estimated stop to polio vaccination

Wild poliovirus February - June 2013



 Endemic country

 Country with WPV case in previous 6 months

Excludes vaccine derived polioviruses and viruses detected from environmental surveillance.

- Historically, the lowest number of cases of wild poliovirus in the fewest countries ever
- Re-spread to countries with new outbreaks in Somalia and Kenya
- With eradication, the proportion of vaccine-derived poliovirus is growing higher


Power of vaccines recognised in prevention of noncommunicable diseases (NCDs)

- Adoption of Global Monitoring Framework for NCDs by WHA
- Recognises vaccines in cancer prevention - Hep B and HPV vaccines are key indicators
- Becomes part of country national planning for prevention of NCDs



66th World Health Assembly, May 2013

Cervical Cancer Global Crisis Card: top 10 mortality rates are GAVI-eligible countries




Source: GLOBOCAN 2008

GAVI Alliance Board meeting
11-12 June 2013



Global maternal and cervical cancer mortality



Sources: Globocan, 2008
Pistani et al, Estimates of worldwide mortality from 25 cancers in 1990. Int J Cancer 1999 83(1) 18-29
WHO UNICEF UNFPA and World Bank, Trends in maternal mortality: 1990-2010



Ten countries approved for HPV vaccine demonstrations


- Kenya
- Ghana
- Lao PDR
- Madagascar
- Malawi
- Niger
- Sierra Leone
- Tanzania
- Mozambique
- Zimbabwe



Mariam, first girl to receive GAVI-supported HPV vaccine – Kenya, May 2013

*GAVI Alliance Board meeting
11-12 June 2013*

Dramatic acceleration



HPV demo projects: examples of country choices for integrating other services

| Country | Complementary interventions |
|------------|---|
| Kenya | Hygiene, nutrition, de-worming |
| Madagascar | Adolescent sexual reproductive health and HIV AIDS prevention |
| Malawi | Gender-based violence |
| Niger | Youth friendly services |

HPV vaccine partnerships



Ministry for Foreign Affairs
Sweden



Senegal's Minister of Health and Zambia's First Lady advocate for vaccines



**WOMEN
DELIVER**
INVEST IN GIRLS AND WOMEN - IT PAYS

*GAVI Alliance Board meeting
11-12 June 2013*



GAVI's new catalytic programme: measles-rubella vaccine

- Rolled out in Rwanda, May 2013
- Five more countries in 2013 –
Bangladesh, Senegal, Cambodia,
Ghana, Vietnam
- Campaigns catalyse self-financed
routine immunisation
- Over 700,000,000 girls and boys
immunised in nearly 50 countries
by 2020




First baby delivered to sitting board member




- Expenditure and resources

Needs and resources 2011-2015



Needs and resources 2016-2020 indicative!



Opportunities and challenges

Alliance supply chain strategy: initial examples

Tracking and tracing vaccines through bar codes




Streamline and improve transparency of short-term forecasting

Country

Global Sources

Short term forecast

New cold chain technology to market



Private sector expertise




Delivering on our promise: 4 million future deaths prevented



*GAVI Alliance Board meeting
11-12 June 2013*


Number of additional children reached




Source: GAVI Alliance, 2013




Plus people immunised through campaigns




Coverage of new and underused vaccines



* Projection



* Projection



* Projection


- Supply constraints
- Country readiness
- In-country coverage

Source: WHO/UNICEF Estimates of National Immunization Coverage, 2012

GAVI Alliance Board meeting
11-12 June 2013



India: pentavalent vaccine introductions 2011-2013



Courtesy: WHO and UNICEF, India

Supply constraints: pneumococcal and rotavirus vaccines

Pneumococcal vaccine

- High demand
- Manufacturing problems
- Supplies may not be available for new applicants until 2015

Rotavirus vaccine

- High demand for 2-dose vaccine – supplies may not be available for new applicants until 2015 or 2016 at the earliest
- 3-dose vaccine available now
- New suppliers in future

India: public private partnership develops breakthrough rotavirus vaccine - *Rotavac*

- Efficacious – phase 3 clinical trials halves (56%) number of severe rotavirus diarrhoea in low-resource settings – comparable to existing rotavirus vaccines
- Low price – Bharat Biotech announces US\$ 1 per dose (3 doses)
- PPP – Bharat Biotech, GoI (DBT), NIH, CDC, Stanford University, PATH, BMGF, DfID, Research Council of Norway
- Formulation issues

India: 100,000 rotavirus deaths per year



Country readiness: Uganda's pneumococcal launch



©UNICEF/2013/Sibiloni

GAVI Alliance Board meeting
11-12 June 2013



Business Plan priority country focus: WHO and UNICEF lead on improving coverage and equity

Lowest coverage countries (<70%)

| | | | |
|-------------|---|---------------|---|
| Afghanistan |  | Uganda |  |
| DRC |  | Guinea |  |
| Haiti |  | South Sudan |  |
| Mauritania |  | Ethiopia |  |
| PNG |  | Cote d'Ivoire |  |
| Somalia |  | Cameroon |  |
| | | Timor Leste |  |

WHO (and other partners) lead

Both low coverage and large inequities

| | |
|---------|---|
| Nigeria |  |
| CAR |  |
| Chad |  |
| Liberia |  |

Joint lead

Largest inequities in coverage

| | |
|------------|---|
| Yemen |  |
| India |  |
| Pakistan |  |
| Mozambique |  |
| Vietnam |  |
| Madagascar |  |

UNICEF lead

Nigeria: encouraging developments

- Background
 - Alarming stockouts in 2011 and early 2012
 - 2011 - DTP3 coverage 47%
 - Partners' concern around polio campaigns undermining routine immunisation
- Government and partners re-invigorate efforts
- Government reports 53% decline in number of unimmunised children in 12 months to March 2013


Nigeria: GAVI support

- GAVI with Government and partners developing new tailored approach – state focus
- Cash support for increasing coverage
 - Previous HSS support reprogrammed.
 - US\$ 50 m - nearly half for cold chain (US\$ 21m)
 - Nigeria may request US\$ 80 m (2014-18) plus potentially US\$ 20 m in performance payment related to DTP3 and MCV1 coverage (PBF)
- Vaccine support
 - Pentavalent currently phasing in nationwide – on track with ambitious plan
 - Pneumococcal approved, introduction subject to supply
 - 2013 campaigns for Meningitis A, Yellow Fever, measles

Health Systems Strengthening (HSS) support

- Focus on immunisation outcomes with performance-based funding
- More results driven:
 - Integrate campaigns into national health systems
 - Synergies with broader maternal and child health
 - Strengthening information systems/data quality
 - Better technical support and capacity building
- Stronger grant management and accountability
- More effective collaboration through the International Health Partnership (IHP+)


HSS: greater focus on results



New HSS proposals: India as an example

- Last polio case 2011 - significant polio infrastructure
- Applying lessons learned from states which raised routine coverage while stopping polio, and moving staff to areas with low coverage
- In parallel with GoI-WHO discussions about sustainability and integrating resources more fully into GoI systems
- Electronic Vaccine Intelligence Network will enable real-time information on cold chain temperatures and vaccine stocks
- Pilot for PPP model in Uttar Pradesh and Bihar to improve vaccine and logistics supply chain from state to last cold chain points

Co-financing: fulfilment of commitments



- Afghanistan**
- Angola
- CAR**
- Congo
- DRC**
- Guinea**
- Niger**
- Pakistan
- Sudan**

- Still in arrears
- Late payment
- Timely co-financing




Working closely with graduating countries

- Facilitating tiered pricing
- Technical assistance
- Cross-Alliance Task Team on immunisation financing and sustainability
 - Monitoring of co-financing performance
 - Updating fiscal space analysis
 - Assessing potential bottlenecks for graduation and developing transition plans
 - Steering country, regional and global advocacy efforts on financial sustainability



The challenge of rigorous data

DTP3 coverage: Ethiopia



World Bank recommitts to health and GAVI


“Specific actions from the World Bank Group must be part of a wider change in how we work together as a global health community.”

Dr Jim Yong Kim, President, World Bank, addresses World Health Assembly, May 2013



The immunisation landscape

Synergies and shared learnings



Comprehensive immunisation services



Looking ahead

Road to replenishment

Pledging conference
June 2011

Mid-term review
October 2013

Vaccine Investment Strategy
November 2013

GAVI Strategy 2016-20
June 2014

Replenishment

2011

2012

2013

2014

2015

Delivering on the promise: messages

The GAVI Alliance is **delivering on its promise** – and your role in this is vital.


Together we demonstrate:

- Results, **value for money** and return on investment
- A **sustainable** business model for development
- An **innovative** public private partnership

Long-term, predictable funding is critical to our work of saving lives and protecting people's health.


GAVI-supported birth cohort will be cut by 40% by 2020

Birth cohort of GAVI countries eligible for new support (million children)



Projected share of spend per vaccine

Excludes Vaccine Investment Strategy



Strategy Discussion Questions

Parameters for the GAVI Strategy for 2016-2020

Context

- What do you think are the key contextual changes in the 2016-2020 period that could affect the strategic directions of the Alliance?

Mission

- To what extent, if at all, do you think GAVI's mission should be modified?

Strategic goals

- To what extent are these appropriate for GAVI's next phase, 2016-2020?
- To what extent should GAVI place emphasis on one or another of these goals?

Eligibility

- In the next strategy period, to what extent, if at all, should GAVI's eligibility criteria be modified?

Operating model

- To what extent is GAVI's current operating model appropriate/"fit for purpose"?

Operating principles

- To what extent do you see these as still "fit for purpose"?

GAVI Alliance strategy development process



Expanding the base

- World Economic Forum
- Islamic Development Bank
- Vaccines Summit
- Women Deliver
- Tokyo International Conference on African Development (TICAD)



Board agenda: key decisions and themes for discussion

Key decisions:

- Inactivated polio vaccine and routine immunisation
- First decisions on Vaccine Investment Strategy
- Grant application, monitoring and review changes
- Themes for discussion:
 - Strengthening routine immunisation
 - Road towards the replenishment
 - Priority countries



www.gavialliance.org